PARADIGM PARAvalvular Leak Closure With the Amplatzer Valvular Plug occluDer for Interventional Transcatheter Closure for PVL With Surgical bioloGical and Mechanical Heart Valve

Status: Recruiting
Location: See all (29) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject is implanted with a mechanical or biological surgical valve in the aortic or mitral position

• Note: Subjects in European countries can only be implanted with a mechanical valve in the aortic or mitral position

• Subject has a clinically significant paravalvular leak with a severity grade of moderate or higher, associated with signs of heart failure and/or hemolysis necessitating recurring blood transfusions.

• Subject has one clinically significant PVL defect that can be closed with a single AVP III as assessed pre-procedurally

• Subject has provided written informed consent

• Subject is ≥18 years old

Locations
United States
Alabama
University Hospital - Univ. of Alabama at Birmingham (UAB)
RECRUITING
Birmingham
Georgia
Emory University Hospital
RECRUITING
Atlanta
Indiana
St. Vincent Hospital
WITHDRAWN
Indianapolis
Louisiana
Ochsner Medical Center
RECRUITING
New Orleans
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Michigan
Henry Ford Hospital
WITHDRAWN
Detroit
Minnesota
Minneapolis Heart Institute
RECRUITING
Minneapolis
Mayo Clinic
WITHDRAWN
Rochester
Missouri
St. Luke's Hospital
RECRUITING
Kansas City
Nebraska
University of Nebraska Medical Center
RECRUITING
Omaha
New Jersey
Hackensack University Medical Center
RECRUITING
Hackensack
New York
Lenox Hill Hospital
RECRUITING
New York
New York Presbyterian Hospital/Cornell University
RECRUITING
New York
Ohio
The Cleveland Clinic Foundation
RECRUITING
Cleveland
Tennessee
Baptist Memorial Hospital
RECRUITING
Memphis
Utah
Intermountain Medical Center
RECRUITING
Murray
Virginia
Carilion Roanoke Memorial Hospital
RECRUITING
Roanoke
Washington
Providence Sacred Heart Medical Center
RECRUITING
Spokane
Other Locations
Canada
Institut de Cardiologie de Montreal (Montreal Heart Inst.)
ACTIVE_NOT_RECRUITING
Montreal
Institut de Cardiologie de Quebec (Hôpital Laval)
ACTIVE_NOT_RECRUITING
Québec
St. Paul's Hospital
WITHDRAWN
Vancouver
Italy
Ospedale San Raffaele
ACTIVE_NOT_RECRUITING
Milan
Netherlands
St. Antonius Ziekenhuis
ACTIVE_NOT_RECRUITING
Nieuwegein
Poland
Gornoslaskie Centrum Medyczne im.prof. Leszka Gieca
ACTIVE_NOT_RECRUITING
Katowice
Spain
Hospital Ramón y Cajal
ACTIVE_NOT_RECRUITING
Madrid
Hospital Universitario de Salamanca
ACTIVE_NOT_RECRUITING
Salamanca
United Kingdom
The Royal Sussex County Hospital
ACTIVE_NOT_RECRUITING
Brighton
Papworth Hospital NHS Foundation Trust
ACTIVE_NOT_RECRUITING
Cambridge
Edinburgh Heart Centre
ACTIVE_NOT_RECRUITING
Edinburgh
Contact Information
Primary
Leslie Centeno
leslie.centeno@abbott.com
818-294-3041
Backup
Leslie Ornelas
leslie.ornelas@abbott.com
480-306-7436
Time Frame
Start Date: 2020-12-01
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 200
Treatments
Experimental: Paravalvular Leak Closure
Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
Related Therapeutic Areas
Sponsors
Leads: Abbott Medical Devices

This content was sourced from clinicaltrials.gov